2024
Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023
Havlik J, Wahid S, Teopiz K, McIntyre R, Krystal J, Rhee T. Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023. Current Psychiatry Reports 2024, 26: 176-213. PMID: 38386251, DOI: 10.1007/s11920-024-01494-4.Peer-Reviewed Original ResearchTreatment of treatment-resistant depressionTreatment-resistant depressionMedication discontinuation ratesTranscranial magnetic stimulationElectroconvulsive therapyPsychiatric approachApproach to treatmentAdjunctive pharmacotherapyIntervention approachesAdjunctive treatmentDiscontinuation ratesMagnetic stimulationGeneralizability resultsDepressionPharmacotherapyInclusion criteriaAntipsychoticsPsychotherapyNarrative reviewKetamine/esketamineSide effectsStudy inclusion criteriaRecent FindingsRecent evidenceDisordersBuprenorphine
2023
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
Krystal J, Kaye A, Jefferson S, Girgenti M, Wilkinson S, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2305772120. PMID: 38011560, PMCID: PMC10710048, DOI: 10.1073/pnas.2305772120.Peer-Reviewed Original Research
2017
Correlates of Nonimprovement to Pharmacotherapy for Chronic, Antidepressant-Resistant, Military Service–Related Posttraumatic Stress Disorder
Byrne SP, Krystal JH, Rosenheck RA, Vessicchio J, Pietrzak RH. Correlates of Nonimprovement to Pharmacotherapy for Chronic, Antidepressant-Resistant, Military Service–Related Posttraumatic Stress Disorder. Journal Of Clinical Psychopharmacology 2017, 37: 717-721. PMID: 28945664, DOI: 10.1097/jcp.0000000000000777.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive AgentsAntipsychotic AgentsDrug Therapy, CombinationFemaleHumansMaleMiddle AgedOutcome Assessment, Health CareRandomized Controlled Trials as TopicRisperidoneSeverity of Illness IndexStress Disorders, Post-TraumaticUnited StatesUnited States Department of Veterans AffairsVeteransConceptsPosttraumatic stress disorderAdjunctive risperidoneTreatment-resistant posttraumatic stress disorderClinician-Administered PTSD Scale scoresSymptom clustersStress disorderOriginal treatment regimenFirst-line pharmacotherapySpecific symptom clustersSpecific PTSD symptom clustersVeterans RANDTreatment regimenPharmacotherapeutic effectsHealth SurveyRole functioningPTSD symptom clustersTreat conditionScale scoreGreater severityVariable improvementRisperidoneTargeted pharmacotherapyPlaceboNonimprovementPharmacotherapy
2016
PTSD: from neurobiology to pharmacological treatments
Kelmendi B, Adams TG, Yarnell S, Southwick S, Abdallah CG, Krystal JH. PTSD: from neurobiology to pharmacological treatments. European Journal Of Psychotraumatology 2016, 7: 31858. PMID: 27837583, PMCID: PMC5106865, DOI: 10.3402/ejpt.v7.31858.Peer-Reviewed Original ResearchPosttraumatic stress disorderPharmacological treatmentPathophysiology of PTSDFirst-line pharmacotherapyMultiple neurobiological systemsEtiology of PTSDFull remissionTherapeutic effectPsychiatric disordersPharmacologic targetStress disorderNeurobiological systemsPathophysiologyFuture targetsTreatmentTraumatic eventsDisordersRemissionPharmacotherapyEtiologyInjurySymptomsYearsWeeks
2009
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today 2009, 14: 690-697. PMID: 19460458, PMCID: PMC2898127, DOI: 10.1016/j.drudis.2009.05.002.Peer-Reviewed Original ResearchConceptsPsychiatric disordersSymptomatic reliefMood disordersAnxiety disordersNeuroplasticity deficitsCurrent pharmacotherapyUnderlying abnormalityCurrent treatmentPsychiatric treatmentNeuroplasticityDisordersPharmacotherapyTreatmentExciting new findingsSchizophreniaReliefAbnormalitiesNeurodevelopmentNew findingsPrevention
2008
Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.
Krishnan-Sarin S, O'Malley S, Krystal JH. Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. Alcohol Research 2008, 31: 400-7. PMID: 23584013, PMCID: PMC3860468.Peer-Reviewed Original ResearchConceptsAlcohol dependenceCurrent treatment optionsAlcohol-drinking behaviorDifferent neurochemical systemsAdjunctive treatmentModest efficacyTreatment optionsNew medicationsNew pharmacotherapiesMedicationsHealth problemsNeurochemical systemsPharmacotherapyTreatmentGreat needCertain genesNaltrexoneAlcoholismDisulfiramDrinkers
2007
Neuroplasticity as a Target for the Pharmacotherapy of Psychiatric Disorders: New Opportunities for Synergy with Psychotherapy
Krystal JH. Neuroplasticity as a Target for the Pharmacotherapy of Psychiatric Disorders: New Opportunities for Synergy with Psychotherapy. Biological Psychiatry 2007, 62: 833-834. PMID: 17916459, DOI: 10.1016/j.biopsych.2007.08.017.Peer-Reviewed Original Research
1999
Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients
Krystal J, D'Souza D, Madonick S, Petrakis I. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 1999, 35: s35-s49. PMID: 10190224, DOI: 10.1016/s0920-9964(98)00162-5.Peer-Reviewed Original ResearchConceptsSchizophrenic patientsSubstance abuseTerms of rehospitalizationComorbid substance abuseExacerbation of symptomsHealth care expensesSelf-medication hypothesisBetter prognosisMedical illnessPharmacotherapeutic approachesRational pharmacotherapyNonschizophrenic populationsPatientsVocational functionIllicit substancesCare expensesAbuseVulnerability hypothesisRehospitalizationExacerbationMedicationsPharmacotherapyPrognosisPsychostimulantsIllness
1991
Follow-up Study of Patients With Panic Disorder-Reply
Nagy L, Krystal J, Charney D, Woods S. Follow-up Study of Patients With Panic Disorder-Reply. JAMA Psychiatry 1991, 48: 861-862. DOI: 10.1001/archpsyc.1991.01810330085018.Peer-Reviewed Original Research